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Abstract
Background Surgery is the cornerstone of treatment of symptomatic cartilaginous neoplasms. We previously studied the appli-
cation of radiofrequency ablation of atypical cartilaginous tumours in the long bones. The purpose of the present study was to
investigate the additional effect of placing multiple needles and a longer procedure duration on the proportion of completely
ablated tumours. Post-ablation MRI findings and the occurrence of complications were also assessed.
Methods We prospectively included 24 patients with atypical cartilaginous tumours in the long bones. Patients underwent CT-
guided radiofrequency ablation followed by curettage with adjuvant phenolisation 3 months later, retrieving material assessed for
viable tumour. Before curettage, gadolinium-enhanced MRI was performed to check for residual tumour. The occurrence of
complications was noted.
Results Complete tumour ablation was achieved in 17 out of 24 patients (71%). Complete ablation was achieved in 5 of the 6
cases (83%) when multiple needles were used in tumours ≥30 mm. There was incomplete ablation in 8% of patients. Post-
ablation gadolinium-enhanced MRI findings agreed with the histological results in 17 out of 23 cases and there was a negative
predictive value of 83%. One patient suffered a fracture after radiofrequency ablation.
Conclusion Radiofrequency ablation could be an alternative to curettage when treating atypical cartilaginous tumours in the long
bones. It was shown that multiple needle placement in addition to longer duration of the ablation procedure is an effective
measure in achieving complete ablation in tumours ≥30 mm. Gadolinium-enhanced MRI has a negative predictive value of 83%
and could guide post-ablation follow-up.
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Introduction
Atypical cartilaginous tumours (ACTs), also known as
chondrosarcoma grade I, are bone tumours of borderline or
low malignant potential [1]. These lesions increasingly pres-
ent as a coincidental finding, when patients are evaluated for
other bone- or joint-related conditions [2–4]. ACTs are a type
of cartilage-forming neoplasm, but unlike higher-grade tu-
mours they do not generally metastasise (<2%) and show
excellent survival rates, with <3% local recurrences [5].
Correct diagnosis in the past has been deemed rather difficult,
as histological or radiological features alone are not always
conclusive [6]. Consequently, tumour upgrading was seen in
some cases of local recurrence. For this reason, wide resection
of the bone and surrounding tissue used to be recommended
sometimes even as primary treatment to avoid this risk [7].
However, recent literature shows that atypical cartilaginous
tumours in the appendicular skeleton can be safely treated
by curettage with adjuvant phenolisation or cryotherapy, pro-
vided that local recurrence rates are low (0–7.7%) and have no
negative effect on patient survival [5, 6, 8–16]. Application of
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this surgical technique has led to an improvement in function-
al results, although complications such as fracturing may still
occur in up to 13% of cases [6, 8–13]. In this context, the
tumour biology should be weighed against the morbidity of
intralesional surgery. For this reason, some favour a conserva-
tive approach, but data are scarce and only retrospective [17].
Minimally invasive treatment may be an alternative, with the
advantage of local control, but largely without the burdens of
conventional surgery.
In orthopaedic oncology there is increasing interest in the
thermal ablation of bone tumours. Radiofrequency ablation
(RFA) is a minimally invasive and highly accurate treatment
tool. Thermal ablation by RFA has become the gold standard
for treatment of certain benign bone tumours (i.e. osteoid os-
teomas) and can be advantageous in the treatment of skeletal
metastases or solid organ tumours (i.e., renal cell carcinoma
and hepatocellular carcinoma) [18–21].
In a previous proof-of-principle study by our group, abla-
tion efficacy of RFA in ACTs was assessed by MRI and sub-
sequent histological examination of ablated tumour tissue.
Occurrence of complications and short-term functional out-
come were also assessed [22]. Complete necrosis was
achieved in 45% of patients, whereby size and localisation
of the tumour were the main predictors of failure. This result
was promising but not satisfactory. Tumours more than
30 mm in diameter were prone to incomplete ablation. The
significance of the Bheat sink^ effect could not be demonstrat-
ed. We therefore altered the protocol so that tumours ≥30 mm
were to be ablated using multiple needle placement. We also
increased the amount of energy delivered with more ablation
cycles. The purpose of the current study is to report on the
effect of these measures on the proportion of completely ab-
lated tumours, the correlation with post-ablationMRI findings
and the occurrence of complications.
Materials and methods
Design
A prospective cohort study was conducted among patients
with ACT in the long bones. Inclusion criteria were: patients
aged ≥18 with a diagnosis of ACT in the long bones on MRI
(e.g. septonodular gadolinium enhancement, no or limited
endosteal scalloping, no perilesional oedema), who opted for
surgical intervention (Fig. 1). Other indications for surgery
were growth of the tumour over time and/or persistent pain
at the tumour site. Tumour size was limited to 50 mm maxi-
mum diameter in any plane. Tumours were not included if
located in the hand, foot, pelvis or axial skeleton. Other ex-
clusion criteria were the presence of cognitive impairments,
cortical breakthrough and previous treatment of the same le-
sion. Written informed consent was obtained from all
participants. The study was approved by the medical ethical
review committee of our hospital (METc no. M09.077334).
All procedures performed in studies involving human partic-
ipants complied with the ethical standards of the institutional
and/or national research committee and with the 1964
Declaration of Helsinki and its subsequent amendments or
comparable ethical standards.
Methods: ablation and surgical technique
A CT-guided biopsy under general or spinal anaesthesia,
followed by RFA in the same session, was conducted as pre-
viously reported [22]. Three months later, gadolinium-
enhanced magnetic resonance imaging (Gd-MRI) was per-
formed to assess for completeness of tumour ablation, follow-
ed within 4 weeks by curettage and adjuvant phenolisation.
The ablation session was performed by one of our consultant
musculoskeletal interventional radiologists using a Soloist™
Single Needle Electrode (Boston Scientific, Natick, MA,
USA; Fig. 1). The session started with 2 W, adding 1 Wevery
minute, and ended automatically when the needle reached its
point of roll-off due to highly elevated impedance of the ab-
lated tissue. Multiple needle placement was applied when in-
complete ablation was anticipated in tumours measuring
≥30 mm (Fig. 2). Material obtained during biopsy was exam-
ined by a pathologist with special expertise in bone and soft-
tissue tumours (A.S). Patients were discharged from the hos-
pital on the same day.
Curettage was performed in accordance with our usual pro-
cedure: a cortical window was created and the lesion was
curetted (Fig. 3). After removal of the tumour, phenolisation
of the cavity was carried out for 2 min, followed by ethanol
washout and saline rinsing. Polymethylmethacrylate (PMMA)
was used to fill the defect in all cases. The retrieved material
was sent to pathology for histological confirmation of ACT
and assessment of the proportion of necrotic tumour tissue.
All surgical procedures were performed by one of two ortho-
paedic oncologists (P.J. and J.P.).
Pathology
The endpoint was the success rate expressed as a percentage
of patients in whom tumour ablation was complete on histol-
ogy. Reaching 100% cell necrosis was regarded as a pR0
response. Subtotal (95–99%) or incomplete (<95%) tumour
eradication were considered pR1 and pR2 respectively.
Correlation with post-ablation Gd-MRI findings was noted,
in addition to the occurrence of complications.
Radiology
Measurements of tumour size (largest diameter in any plane)
were based on 4-mm slice MR images and 1.5-mm slice CTs.
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Imaging was also analysed using a grading system that includ-
ed three categories: no signs of residual tumour (rR0), little or
doubtful gadolinium uptake at the tumour border (rR1), and
clear residual tumour outside the ablation zone (rR2). Needle
positioning was assessed retrospectively. All post-RFA Gd-
MRI were graded by a musculoskeletal radiologist (J.O.),
who was blinded to the histological results.
Statistical analysis
Mean and range of values were noted for all variables. SPSS
version 22.0 software (IBM-SPSS, Armonk, NY, USA) was
used for all statistical testing. If applicable, a univariate anal-
ysis was undertaken using Student’s t test for normally distrib-
uted values and the Mann–Whitney U test for non-parametric




In total, 24 patients were included, with a mean age of
51.1 years (range 31–75). The femur was affected most (n =
16), followed by the humerus (n = 5) and tibia (n = 3). Mean
tumour size was 28.3 mm (range 15–43). Six patients received
multiple needle placement, all in tumours measuring ≥29 mm.
The RFA procedure took on average 23.6 min (range 12–37;
Fig. 1 a Representative MRI of
an atypical cartilaginous tumour
(ACT) in the proximal femur. b
Transverse and c coronal images
of CT-guided radiofrequency
ablation (RFA) of the same
tumour
Fig. 3 Exposure of the bone to reach the tumour through a cortical
window that has to be created. Note the scar from the previous insertion
of an RFA needle (white arrow)
Fig. 2 Radiofrequency ablation procedure of an ACT in the proximal
humerus with two-needle placement
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Table 1). In one patient, a Gd-MRI after RFAwas not made, as
a fracture occurred before the planned date of the scan. It was a
low-energy fracture, 7 weeks after the index ablation proce-
dure. Curettage was performed, followed by mini-open plate
fixation without reduction. A non-union developed that need-
ed second surgery with reduction, bone graft and plate fixa-
tion. The fracture healed well. This patient was still included
for histological analysis purposes.
Proportion of completely ablated tumours
On a histological level, total ablation (pR0) was reached in 17
out of 24 cases (71%). Incomplete ablation (pR2) was present
in 2 out of 24 (8%) and subtotal ablation (pR1) in 5 out 24
(21%) cases. In diaphyseal tumours, pR0 response was
achieved in 13 out of 15 (87%) cases compared with 4 out
of 9 for metaphyseal tumours (p = 0.027). Duration of the
ablation procedure was 24.4 min (range 14-37) in pR0,
23.6 min (range 14-34) in pR1 and 16.5 min (range 12-21)
in pR2 cases (p =NS).
Correspondence with Gd-MRI
Complete ablation was correctly diagnosed as rR0 in 15 out of
16 cases, with the other case judged as rR1; pR1 corresponded
with rR1 in 2 out of 5 and rR0 in 3 out of 5 cases respectively.
The cases with a pR2 response were considered rR1 (1 out of
2) and rR2 (1 out of 2; Table 2).
Needle positioning
For tumours measuring ≤30 mm needle positioning was cen-
tric in 11 out of 14 cases, eccentric in 2 cases, and in 1 case
multiple needles were applied in a 29-mm diameter tumour.
For tumours measuring >30 mm, needle placement was cen-
tric in 4 out of 10 cases, multiple needles were applied in 5 out
of 10 cases, and in 1 case of a 31-mm tumour the needle was
placed eccentrically (Fig. 4). In 1 out of 2 pR2 cases the needle
was placed eccentrically (non-significant compared with pR0
and/or pR1 cases). In tumours measuring >30 mm, centric or
multiple needle positioning led to pR0 in 7 out of 10 patients
and pR1 in 2 out of 10. This group had one pR2 in which the
Table 1 Patient characteristics and outcome
Case
number




Needles Histological response Radiological response Complications
1 56 Female Femur (M) 24 22 Single Focal residue Focal uptake None
2 63 Female Femur (M) 21 19 Single Complete necrosis No uptake None
3 51 Female Femur (M) 30 25 Single Complete necrosis No uptake None
4 67 Female Femur (M) 27 29 Single Complete necrosis No uptake None
5 49 Female Femur (D) 35 23 Multiple Complete necrosis No uptake None
6 43 Female Humerus (D) 15 19 Single Complete necrosis No uptake None
7 31 Male Femur (M) 28 34 Single Focal residue No uptake None
8 52 Female Humerus (D) 29 14 Multiple Complete necrosis No uptake None
9 46 Female Femur (M) 31 21 Single Substantial residue Substantial uptake None
10 49 Female Humerus (D) 29 29 Single Complete necrosis Focal uptake None
11 53 Female Tibia (D) 24 26 Single Complete necrosis No uptake None
12 48 Female Femur (D) 22 17 Single Complete necrosis No uptake None
13 63 Female Femur (D) 29 37 Single Complete necrosis – Fracture
14 48 Male Femur (D) 21 15 Single Complete necrosis No uptake None
15 58 Female Femur (M) 24 12 Single Substantial residue Focal uptake None
16 63 Male Humerus (D) 34 21 Multiple Complete necrosis No uptake None
17 40 Female Humerus (D) 36 19 Multiple Complete necrosis No uptake None
18 59 Female Femur (D) 36 14 Multiple Focal residue No uptake None
19 33 Female Femur (D) 31 31 Single Complete necrosis No uptake None
20 31 Male Femur (D) 30 21 Single Focal residue Focal uptake None
21 50 Female Tibia (D) 43 31 Multiple Complete necrosis No uptake None
22 75 Female Femur (M) 36 35 Single Complete necrosis No uptake None
23 49 Female Femur (M) 26 27 Single Focal residue No uptake None
24 47 Female Tibia (D) 19 25 Single Complete necrosis No uptake None
Mmetaphysis, D diaphysis
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needle was placed eccentrically. When multiple needles were
used, complete ablation was achieved in all but 1 case.
Discussion
We demonstrated in 71% of patients that complete tumour
necrosis is achievable using RFA for ACT in the long bones.
Implementation of multiple needle placement in larger tu-
mours and longer procedure duration improved ablation effec-
tiveness. After our previous proof-of-principle study, we pre-
sented three possible causes of a failed ablation procedure:
1. Number and total ablation time of cycles
2. Tumour size (> 30 mm)
3. Heat sink effect
We slightly adjusted our study ablation technique by deliver-
ing more local energy, either by multiple needles or longer
ablation duration [22]. We found that in all but 1 case com-
plete ablation was achieved when multiple needles were used.
Time is an issue, as temperature rise is a result of conductivity;
hence, the longer the procedure takes, the more tissue is heat-
ed. Whether the heat sink effect plays a major role in the
difference between success rates in metaphyseal and diaphy-
seal tumours is questionable, but more heat loss to surround-
ing tissue is plausible in metaphyseal bone if the thinness of
the cortex and the higher vascularity of the metaphysis are
considered [23].
Although a quantitative comparison with our previous
study was not performed, the achieved level of complete ne-
crosis in 71% of the participants was higher than in the proof-
of-principle study (45%), with a decrease in evident failures
from 30 to 8% in the current study. Based on univariate anal-
ysis, diaphyseal tumours are most amenable for RFA treat-
ment, with an 87% success rate. There were 2 patients with
substantial viable tissue after ablation. In 1 case, the total
ablation time was relatively short (12 min). In the other case,
the needle was placed eccentrically and, considering the size
(31 mm), there should have been multiple needle placement.
Both cases can thus be regarded as technical failures and were
not conducted in accordance with our treatment protocol.
Post-ablation Gd-MRI findings corresponded with histo-
logical results in 17 out of 23 cases, with 5 cases under-
staged (the radiological response was better than the histolo-
gy) and 1 case over-staged (the radiological response was
worse than the histology). Fifteen out of 18 cases were cor-
rectly diagnosed as R0 on Gd-MRI (NPV = 83%). We want to
stress that both failures (pR2) were seen on Gd-MRI, with one
regarded as rR1. There is a chance of a small amount of re-
sidual tumour (pR1) being overlooked, but development of
local recurrence (out of residue) is very gradual and has no
negative effects on patient survival according to the current
literature [5]. A recent paper has proposed a classification of
MRI response after curettage with a consequent follow-up
regime, which in our opinion can be extrapolated to MRI after
ablation [24].
Despite the increased efficacy rates compared with our ini-
tial proof-of-principle study, there is still room for improve-
ment. We are currently studying needle placement planning,
in which ideally an algorithm can be developed using com-
puter modelling and planning with computer-assisted surgery
(CAS) to determine and execute optimal needle positioning,
especially when multiple probe positions are used. Moreover,
a needle that is regulated by temperature sensors instead of
impedance could generate a more predictable ablation zone.
Real-time imaging of the lesion during ablation would be of
great value to monitor the ablation effect, albeit technically
demanding. Needles used for thermal ablation are not MRI-
compatible, and currently CT cannot detect temperature
changes during RFA. Finally, an alternative might be the use
Table 2 Correlation of Gd-MRI
with histological findings Gd-MRI
No uptake Focal uptake Substantial uptake Total
pathology Complete necrosis 15 1 0 16
Focal residue 3 2 0 5
Substantial residue 0 1 1 2
Total 18 4 1 23
Fig. 4 Radiofrequency ablation procedure of ACT in the proximal
humerus, with eccentric placement of the needle
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of microwave ablation (MWA), as it is less dependent on
tissue conductivity than RFA [25].
Our study also has some limitations. Only relatively small
lesions were ablated and long-term follow-up after RFA is lack-
ing. Some lesions might arguably have been enchondroma; yet,
imaging and biopsy results convinced us of ACT in all cases. In
addition, this study was designed as proof-of-principle for
whether thermal ablation can treat chondroid tumours and to
investigate the reliability of Gd-MRI to check for viable tumour
post-ablation. For that reason, curettage served as a control for
the effects of RFA at a histological level and assess correspon-
dence of post-RFA histology with Gd-MRI. In the future, RFA
will be investigated as a treatment tool instead of curettage, to
draw definitive conclusions after adequate follow-up.
To summarise, we have demonstrated that RFA is capable of
ablating ACTs in the long bones in 71% of cases, especially
diaphyseal tumours. However, long-term follow-up is lacking
and future studies should de designed to assess long-term out-
come after RFAwithout subsequent curettage. It should be noted
that for many years there has been a dearth of surgical innova-
tions in the treatment of bone tumours, and we believe that the
use of local tumour ablation can be a very valuable adjunct to
current treatment options. We stress that not all ACTs are candi-
dates for surgery, and yet there is neither a clear consensus on a
conservative approach nor clear definitions of indications for
surgery [17]. With this study, we have shown that multiple nee-
dle placement in addition to longer duration of the ablation pro-
cedure is an effective measure for achieving complete tumour
ablation in tumours measuring ≥30 mm. Gadolinium-enhanced
MRI has a negative predictive value of 83% and could safely
guide follow-up after RFA. Future studies should focus on plan-
ning,monitoring and further improving ablation efficacy byRFA
technique, with adequate follow-up after the ablation procedure.
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